Table 7 Incremental effectiveness and costs from our base-case analyses (drotrecogin alfa compared to placebo)
Model | Incremental Cost (95% CI) | Incremental effectiveness (LYG) | % simulations where drotrecogin alfa has a lower effectiveness than placebo |
|---|---|---|---|
All patients | $11,024 ($8,670, $13,341) | 0.344 (-0.807, 1.476) | 27% |
APACHE II ≥ 25 | $13,612 ($9,785, $17,421) | 1.191 (-0.082, 2.417) | 3% |